QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Files An 8-K Other Events
Item8.01
| Other Events |
On May 24, 2017, the Companys Board of Directors increased the
stock authorization under its previously approved equity
repurchase program (the Repurchase Program) by $1 billion.After
giving effect to the increase, the Company has authority to
repurchase approximately $1.15 billion of shares of common stock
as of May 24, 2017.
The Repurchase Program does not obligate the Company to
repurchase any particular amount of common stock, and it may be
modified, suspended or discontinued at any time. The timing and
amount of repurchases are determined by management based on a
variety of factors such as the market price of the Companys
common stock, the Companys corporate requirements, and overall
market conditions. Purchases of common stock may be made in open
market transactions effected through a broker-dealer at
prevailing market prices, in block trades, or in privately
negotiated transactions. The Company may also repurchase shares
of common stock to a trading plan meeting the requirements of
Rule 10b5-1 under the Securities Exchange Act of 1934, as
amended, which would permit shares of common stock to be
repurchased when the Company might otherwise be precluded from
doing so by law. The Repurchase Program does not have an
expiration date.
As previously reported, on October3, 2016, Quintiles
Transnational Holdings Inc. (Quintiles) completed a merger of
equals transaction (the Merger) with IMS Health, which is more
fully described in Quintiles Current Report on Form 8-K filed on October3, 2016.
to the terms of the merger agreement dated as of May3, 2016
between Quintiles and IMS Health, in connection with the closing,
IMS Health was merged with and into Quintiles, and the separate
corporate existence of IMS Health ceased, with Quintiles
continuing as the surviving corporation in the Merger under the
name Quintiles IMS Holdings, Inc.
Included in this
Current Report on Form 8-K are (i)the historical unaudited
condensed consolidated financial statements of IMS Health as of
the dates and for the periods described in Item 9.01 below, as
Exhibit 99.1, (ii) the unaudited pro forma condensed combined
financial statements of QuintilesIMS, giving effect to the
Merger, for the periods described in Item 9.01 below, as Exhibit
99.2, and (iii)the historical audited consolidated financial
statements of IMS Health as of the dates and for the periods
described in Item 9.01 below, as Exhibit 99.3.
| Item9.01 | Financial Statements and Exhibits. |
(a)
Financial statements of businesses acquired.
The unaudited
condensed consolidated statements of financial position of IMS
Health as of September30, 2016 and December31, 2015, the
condensed consolidated statements of comprehensive income for the
three and nine months ended September30, 2016 and 2015, the
condensed consolidated statements of cash flows of IMS Health for
the nine months ended September30, 2016 and 2015, and the notes
related thereto, are attached as Exhibit 99.1 and are
incorporated herein by reference.
The audited
consolidated statements of financial position of IMS Health as of
December31, 2015 and 2014 and the consolidated statements of
comprehensive income (loss), consolidated statements of cash
flows and consolidated statements of shareholders equity of IMS
Health for the years ended December31, 2015, 2014 and 2013 and
the notes related thereto, are attached as Exhibit 99.3 and are
incorporated herein by reference.
(b) Pro
forma financial information.
The unaudited pro
forma condensed combined statements of income of QuintilesIMS for
the year ended December31, 2016, and the notes related thereto,
are attached as Exhibit 99.2 and incorporated herein by
reference.
(d)
Exhibits.
See the Exhibit
Index attached hereto.
About QUINTILES IMS HOLDINGS, INC. (NYSE:Q)
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions. QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Recent Trading Information
QUINTILES IMS HOLDINGS, INC. (NYSE:Q) closed its last trading session up +0.42 at 84.22 with 767,577 shares trading hands.
